acromegaly, healthy
Conditions
Brief summary
GH induced changes in metabolism of energy rich phosphates (ATP turnover)
Detailed description
GH induced changes in hepatic lipid content, GH induced changes in VLDL secretion, GH induced changes in de novo lipogenesis, i.e. the incorporation of D2 into VLDL-TG palmitate and lipid profiling using a DNL index, GH induced changes in the accumulation of deuterium label in lipid stores, including liver and subcutaneous adipose tissue, as measure of depot specific de novo lipogenesis, GH induced changes in resting energy expenditure, GH induced changes in body composition
Interventions
DRUGSOMAVERT 20 mg powder and solvent for solution for injection
DRUGGenotropin® 12 mg/ml Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
Sponsors
Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GH induced changes in metabolism of energy rich phosphates (ATP turnover) | — |
Secondary
| Measure | Time frame |
|---|---|
| GH induced changes in hepatic lipid content, GH induced changes in VLDL secretion, GH induced changes in de novo lipogenesis, i.e. the incorporation of D2 into VLDL-TG palmitate and lipid profiling using a DNL index, GH induced changes in the accumulation of deuterium label in lipid stores, including liver and subcutaneous adipose tissue, as measure of depot specific de novo lipogenesis, GH induced changes in resting energy expenditure, GH induced changes in body composition | — |
Countries
Austria
Outcome results
None listed